Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 14/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937301 | 0.94 | LIMK1 (0.39) | LIMK1CDK5CDK5R1ROCK1LIMK2 | |
| SCHEMBL21263419 | 0.93 | LIMK1 (0.38) | LIMK1CDK5CDK5R1ROCK1LIMK2 | |
| SCHEMBL21263398 | 0.92 | LIMK1 (0.39) | LIMK1CDK5CDK5R1ROCK1PIK3CA | |
| SCHEMBL19936951 | 0.90 | LIMK1 (0.37) | LIMK1CDK5CDK5R1ROCK1EGFR | |
| SCHEMBL19937280 | 0.89 | LIMK1 (0.37) | LIMK1CDK5CDK5R1ROCK1LIMK2 | |
| SCHEMBL21263503 | 0.88 | MEN1 (0.35) | LIMK1ROCK1LIMK2PIM1PIM3 | |
| SCHEMBL21263482 | 0.88 | CYP11B1 (0.38) | LIMK1CDK5CDK5R1ROCK1PIK3CA | |
| SCHEMBL19936993 | 0.88 | CYP11B1 (0.39) | LIMK1CDK5CDK5R1PIK3CAEGFR | |
| SCHEMBL16922473 | 0.87 | LIMK1 (0.43) | LIMK1CDK5CDK5R1ROCK1LIMK2 | |
| SCHEMBL21263342 | 0.87 | LIMK1 (0.38) | LIMK1CDK5CDK5R1ROCK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248804-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | IDEMITSU KOSAN CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| WO-2018043761-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | IDEMITSU KOSAN CO.,LTD. (JP) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248804-A1 | SPECIFICALLY SUBSTITUTED AZA-DIBENZOFURANS AND AZA-DIBENZOTHIOPHENES FOR ORGANIC ELECTRONIC DEVICES | CDY1; CDY1B, CDYL, CBX8 | LIMK1 3482/4885CDK5 4302/4885CDK5R1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.